Does a Protein That Cleans Synapses Really Slow Down Parkinson's

Introduction: the brain's forgotten deep clean

Synapses clogging up long before the first symptoms

Long before the first clinical signs of diseases like Parkinson's or Alzheimer's appear in a patient, a silent process is already unfolding at the microscopic scale in the brain: synapses, those essential contact points between neurons, gradually begin clogging up with poorly cleared protein debris. This quiet process may be one of the very first links in the chain that leads, years later, to the most feared neurodegenerative diseases.

This debris, often made up of misfolded or damaged proteins, normally accumulates only marginally in any living cell, but its efficient removal depends on a sophisticated cellular cleanup system. When this system weakens, particularly at the synapses, which are extremely energy-hungry and require rapid protein turnover, the consequences can ripple through the entire neuronal function of the person affected.

This gradual buildup, often described by researchers as synaptic congestion, may explain why so many neurodegenerative diseases progress silently for many years before the patient or those around them notice the first telltale clinical signs.

A laboratory focused on the cellular waste-removal system

This is precisely the mechanism that the laboratory led by researcher Hermann Steller, at Rockefeller University, chose to study, focusing closely on a protein called PI31, whose central role is to transport proteasomes to the synapses. Proteasomes act as genuine cellular trash bins, tasked with breaking down proteins that have become useless or toxic before they accumulate dangerously.

Published in 2025, the results obtained by this research team open up a therapeutic avenue that directly targets the early mechanisms of synaptic congestion, rather than focusing solely on the already well-established late symptoms of the most common neurodegenerative diseases in humans.

PI31, the delivery truck for cellular trash

Understanding the role of proteasomes in the cell

To fully grasp the importance of this discovery, one must first understand what proteasomes are: genuine specialized molecular complexes, present in every cell of the human body, whose function is to cut up and eliminate proteins that are damaged, misfolded, or simply obsolete after fulfilling their biological role.

Without this constant elimination system, defective proteins would quickly build up inside cells, disrupting their normal functioning and potentially causing a genuine toxic clog. This phenomenon is especially critical at the synapses, the communication zones between neurons that require constant, rapid protein turnover to function properly.

The challenge for the cell, then, is to efficiently deliver these proteasomes to the exact spots where cleanup is most urgently needed, somewhat like a municipal service that needs to send its collection trucks exactly where waste is piling up fastest in a densely populated city.

The transport role fulfilled by PI31

This is precisely the transport role that the PI31 protein plays: it acts as a molecular vehicle, carrying proteasomes from the neuron's cell body all the way to the farthest synapses, where cleaning up protein waste is just as necessary as anywhere else in the cell.

The work of Steller's team showed that by boosting the activity of this transport protein, it becomes possible to significantly improve the delivery of proteasomes to synapses, thereby reducing the local buildup of toxic waste that would otherwise keep accumulating without being effectively handled by the cell.

This discovery is all the more significant because neurons, due to their elongated shape and long extensions, face a particular logistical challenge: unlike a round, compact cell, a neuron must deliver its cleanup resources over considerable distances on a cellular scale, sometimes across several tens of centimeters for the longest axons in the human body.

Spectacular results in flies and mice

Motor functions restored in Parkinson's models

To test their hypothesis, the researchers worked with animal models reproducing certain aspects of Parkinson's disease, using both flies and laboratory mice genetically modified to develop symptoms comparable to those seen in human patients with this neurodegenerative condition.

By artificially raising PI31 levels in these animals, the team observed a notable restoration of motor functions that had previously been impaired by the disease, a result all the more remarkable given that it concerns symptoms usually considered difficult to reverse once established in the animal.

These results suggest that strengthening proteasome transport to the synapses does not merely slow the disease's progression, but could actually help restore certain functional capacities already compromised, which sets this approach apart from many other therapeutic avenues tested so far without comparable success.

Tau buildup also reduced

Beyond motor functions, the researchers also found that this boost to synaptic cleanup reduced the buildup of the tau protein, another protein implicated in several neurodegenerative diseases, including Alzheimer's disease, when it aggregates abnormally in the brain.

This observation considerably broadens the potential scope of the discovery, suggesting that the mechanism identified by Steller's team may not be limited to Parkinson's disease alone, but could more broadly involve the full range of conditions characterized by toxic protein buildup at the synaptic level.

A lifespan extended up to fourfold

A result that surprised the researchers themselves

Among the most striking results of this research is the observation, in certain treated animal models, of a lifespan extended by as much as four times the duration normally observed in untreated animals showing the same Parkinson's-like symptoms.

Such an extension of longevity, in the context of a neurodegenerative disease model usually associated with reduced life expectancy in laboratory animals, is a strong signal of the scale of the biological benefit brought about by strengthening the synaptic cleanup system driven by PI31.

Researchers nonetheless remain cautious about directly extrapolating this result to humans, since aging and disease mechanisms in flies or mice do not always translate proportionally to a species as complex as our own.

The lead researcher's words on the scope of the discovery

Researcher Hermann Steller himself stressed the importance of this discovery, explaining that a number of diseases are, in reality, diseases of synaptic dysfunction, at least in their initial stages, well before broader clinical symptoms become apparent in the patient.

He added that he hopes this advance, by showing how to eliminate unwanted proteins directly at the synapse, could contribute to a genuine revolution in the treatment of age-related disorders, an ambition that reflects the enthusiasm these results have generated within the specialized scientific community.

What this discovery does not yet tell us

Promising results, but still far from the human clinic

It is important to keep in mind that these results, while particularly encouraging, were obtained exclusively in laboratory animal models, and not directly in human patients with Parkinson's disease or other comparable neurodegenerative disorders.

The path between a fundamental discovery in the lab, however promising, and an actual treatment available to patients generally remains long and fraught with uncertainty, requiring years of additional trials before any concrete, large-scale validated clinical application.

Researchers will in particular need to determine how to safely and precisely stimulate PI31 activity in humans, without causing unwanted effects elsewhere in the body, a pharmacological challenge that remains wide open despite the clarity of the biological mechanism the team has now identified.

One lead among others in Parkinson's research

This discovery adds to a much larger body of research currently underway around the world into the root causes of neurodegenerative diseases, without constituting a single, definitive answer to a problem whose origins remain multifactorial and still incompletely understood by science.

It nonetheless illustrates an interesting shift in approach, one that targets the early mechanisms of cellular congestion rather than only the late-stage symptoms, a strategy that, if confirmed, could durably transform how we approach the prevention of these diseases feared by so many families.

Conclusion: a solid lead, but still preliminary

What the available facts confirm today

The data published by Hermann Steller's team do indeed confirm that stimulating the PI31 protein can, in fly and mouse animal models, restore certain motor functions and reduce the buildup of toxic proteins associated with Parkinson's disease, with a notable lifespan extension observed in these controlled experiments.

These results, published in 2025, rest on a rigorous scientific methodology and were highlighted by Rockefeller University among its standout discoveries of the year, reflecting the perceived strength of this advance within the neuroscience research community.

What still needs verifying before talking about treatment

It would nonetheless be premature, at this stage, to claim that this discovery already represents an available, or even imminent, treatment for human patients with Parkinson's or other neurodegenerative diseases. The next stages of research will need to confirm that this mechanism, observed in animals, actually translates in a comparable way in the far more complex and harder-to-study human brain.

Given the current state of knowledge, this discovery therefore stands as a solid, rigorously documented, yet still preliminary therapeutic lead, one that deserves to be followed closely without fueling disproportionate expectations of an immediate cure for diseases affecting millions of people worldwide.

By Maxime Marquette, columnist

Columnist's transparency note

How I fact-checked this claim

This fact-check is based on Rockefeller University's public communications about the Steller laboratory's 2025 findings, along with outlets covering neuroscience and cellular biology. I am not a neuroscientist, and I have relied on the researchers' own statements about what was observed in flies and mice, rather than assuming any direct applicability to human patients.

Given how easily promising animal studies get overstated in public discussion, I have deliberately kept the framing here anchored to what has actually been shown so far, and flagged clearly where the evidence stops and speculation about future human treatment would begin.

Why this distinction between animal models and human disease matters

I chose to spend extra space on the gap between fly and mouse experiments and an eventual human treatment because that is exactly where headlines about Parkinson's research tend to mislead readers the most. A striking result in a genetically engineered fly is not the same thing as a therapy sitting on a pharmacy shelf, and conflating the two does a disservice to patients and families who live with these diseases every day.

My goal with this fact-check was not to dismiss the excitement around PI31, which is genuinely warranted given the rigor of the Rockefeller team's work, but to give readers the tools to separate a strong scientific lead from a proven cure, so they can follow the story with realistic expectations as it develops.

Sources

Primary sources

The Rockefeller University — Intriguing science discoveries of 2025, including the study on PI31 and synapses — 2025

Cell Press — Research on proteasome biology and neurodegenerative diseases — 2025

Nature — Parkinson's Disease: scientific publications on neurodegenerative mechanisms — 2025

Secondary sources

Futura Sciences — Accessible analysis of neurodegenerative diseases — 2025

Sciences et Avenir — Coverage of advances in neuroscience and cell biology — 2025

Science et Vie — Reports on research against Parkinson's and Alzheimer's — 2025